| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
|
Medicine details |
|
| Medicine name | tobramycin (Tobi Podhaler®) |
| Formulation | 28 mg inhalation powder |
| Reference number | 1347 |
| Indication | Suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/11/2011 |
| NICE guidance | |